These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 24925807

  • 1. A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines.
    Barkoff AM, Guiso N, Guillot S, Xing D, Markey K, Berbers G, Mertsola J, He Q.
    J Immunol Methods; 2014 Jun; 408():142-8. PubMed ID: 24925807
    [Abstract] [Full Text] [Related]

  • 2. Pertactin-deficient Bordetella pertussis isolates: evidence of increased circulation in Europe, 1998 to 2015.
    Barkoff AM, Mertsola J, Pierard D, Dalby T, Hoegh SV, Guillot S, Stefanelli P, van Gent M, Berbers G, Vestrheim D, Greve-Isdahl M, Wehlin L, Ljungman M, Fry NK, Markey K, He Q.
    Euro Surveill; 2019 Feb; 24(7):. PubMed ID: 30782265
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. International collaborative study: evaluation of proposed International Reference Reagent of pertussis antiserum (mouse) 97/642.
    Gaines Das R, Xing D, Rigsby P, Newland P, Corbel M.
    Biologicals; 2001 Jun; 29(2):137-48. PubMed ID: 11580218
    [Abstract] [Full Text] [Related]

  • 5. Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.
    Cherry JD, Heininger U, Richards DM, Storsaeter J, Gustafsson L, Ljungman M, Hallander HO.
    Clin Vaccine Immunol; 2010 May; 17(5):741-7. PubMed ID: 20335431
    [Abstract] [Full Text] [Related]

  • 6. Bordetella pertussis isolates in Finland after acellular vaccination: serotype change and biofilm formation.
    Niinikoski V, Barkoff AM, Mertsola J, He Q.
    Clin Microbiol Infect; 2024 May; 30(5):683.e1-683.e3. PubMed ID: 38310999
    [Abstract] [Full Text] [Related]

  • 7. Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.
    Queenan AM, Dowling DJ, Cheng WK, Faé K, Fernandez J, Flynn PJ, Joshi S, Brightman SE, Ramirez J, Serroyen J, Wiertsema S, Fortanier A, van den Dobbelsteen G, Levy O, Poolman J.
    Vaccine; 2019 Jan 03; 37(1):80-89. PubMed ID: 30478007
    [Abstract] [Full Text] [Related]

  • 8. Evolution of Bordetella pertussis over a 23-year period in France, 1996 to 2018.
    Bouchez V, Guillot S, Landier A, Armatys N, Matczak S, French pertussis microbiology study groupThe members of the group are listed under Investigators., Toubiana J, Brisse S.
    Euro Surveill; 2021 Sep 03; 26(37):. PubMed ID: 34533118
    [Abstract] [Full Text] [Related]

  • 9. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
    Debrie AS, Coutte L, Raze D, Mooi F, Alexander F, Gorringe A, Mielcarek N, Locht C.
    Vaccine; 2018 Mar 07; 36(11):1345-1352. PubMed ID: 29433898
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Quantification of cell-associated and free antigens in Bordetella pertussis suspensions by antigen binding ELISA.
    Westdijk J, van den Ijssel J, Thalen M, Beuvery C, Jiskoot W.
    J Immunoassay; 1997 Aug 07; 18(3):267-84. PubMed ID: 9257265
    [Abstract] [Full Text] [Related]

  • 12. Bordetella pertussis isolates in Finland: serotype and fimbrial expression.
    Heikkinen E, Xing DK, Olander RM, Hytönen J, Viljanen MK, Mertsola J, He Q.
    BMC Microbiol; 2008 Sep 25; 8():162. PubMed ID: 18816412
    [Abstract] [Full Text] [Related]

  • 13. Acellular pertussis vaccines and the role of pertactin and fimbriae.
    Poolman JT, Hallander HO.
    Expert Rev Vaccines; 2007 Feb 25; 6(1):47-56. PubMed ID: 17280478
    [Abstract] [Full Text] [Related]

  • 14. Construction and characterization of single-chain variable fragment antibodies directed against the Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin.
    Hussein AH, Davis EM, Halperin SA, Lee SF.
    Infect Immun; 2007 Nov 25; 75(11):5476-82. PubMed ID: 17724067
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy of chemically cross-linked antigens for acellular pertussis vaccine.
    Watanabe M, Nagai M, Funaishi K, Endoh M.
    Vaccine; 2000 Dec 08; 19(9-10):1199-203. PubMed ID: 11137257
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens.
    Macdonald-Fyall J, Xing D, Corbel M, Baillie S, Parton R, Coote J.
    Vaccine; 2004 Oct 22; 22(31-32):4270-81. PubMed ID: 15474718
    [Abstract] [Full Text] [Related]

  • 20. Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of Bordetella pertussis in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults.
    He Q, Tran Minh NN, Edelman K, Viljanen MK, Arvilommi H, Mertsola J.
    Infect Immun; 1998 Aug 22; 66(8):3796-801. PubMed ID: 9673264
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.